Eton Pharmaceuticals Inc
Research Eton Pharmaceuticals Inc (ETON) on Bullrun: valuation model: 65.3% overvalued, market cap USD 1.56B, P/E 145.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerETON
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal65.3% overvalued
- Market capUSD 1.56B
- P/E145.9
- Financial periodQ2 2026
- RevenueUSD 37.59M
- Net incomeUSD 11.58M
- Free cash flowUSD 7.26M
- Gross margin67.6%
Valuation Snapshot
Bullrun's latest valuation model marks Eton Pharmaceuticals Inc as 65.3% overvalued; latest market cap is USD 1.56B; P/E is 145.9.
Peer valuation comparison
Latest P/E is 145.94x versus a Healthcare sector median of 24.61x (493.1% above).
Latest P/E is 145.94x versus a United States median of 23.85x (511.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 79.95M | -USD 4.60M | USD 10.19M | 53.5% | -0.17 | USD 25.94M | USD 30.56M | USD 26.15M |
| FY2024 | USD 39.01M | -USD 3.82M | USD 943.00K | 60.0% | -0.15 | USD 14.94M | USD 29.81M | USD 24.43M |
| FY2023 | USD 31.64M | -USD 936.00K | USD 6.82M | 66.6% | -0.04 | USD 21.39M | USD 5.38M | USD 15.48M |
| FY2022 | USD 21.25M | -USD 9.02M | USD 4.78M | 67.4% | -0.36 | USD 16.31M | USD 6.42M | USD 13.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.56B | 145.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 457.37M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 355.77M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 112.38M | 54.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 71.34M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 105.65M | n/a | n/a | n/a |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Eton Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Eton Pharmaceuticals Inc as 65.3% overvalued.
What is Eton Pharmaceuticals Inc's market cap?
Eton Pharmaceuticals Inc's market capitalization is USD 1.56B.
What is Eton Pharmaceuticals Inc's P/E ratio?
Eton Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 145.9.
What does Eton Pharmaceuticals Inc do?
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.